David Meeker Quote David Meeker Quote Dr. Shoemaker quote Dr. Shoemaker quote IMCIVREE packaging IMCIVREE packaging with vial IMCIVREE 3D...
National Data Reveals Wide Variation in the Adherence to Basic Cognitive Assessment in Dementia CareSAN FRANCISCO, March 19, 2026 /PRNewswire/ --...
Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using...
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of...
Results illustrate how NetraMark’s advanced AI can potentially support precision enrichment strategies in future trialsTORONTO, March 19, 2026 (GLOBE NEWSWIRE)...
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at...
PRI-101 inhibited aggregation of α-synuclein and actively disassembled fibrils across in vitro and in vivo models relevant to Parkinson’s disease...
Brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now available for...
IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- WallabyPhenox, a global neurovascular medical technology company, today announced the successful completion...
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a...
Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies...
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2SK...
– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy – – ARV-102 was well...
New integrative mental health program combines neuroscience, personalized assessments, and evidence-based psychiatric care to help individuals restore energy, resilience, and...
Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ,...
REPORTS YEAR OF STRATEGIC TRANSFORMATION AND CLINCIAL ADVANCEMENT SARASOTA, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:...
SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...
Chronos‑PD shows that biological changes associated with Parkinson’s disease (PD) can emerge up to 12 years before clinical diagnosisUncovered reproducible...
NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics...
Novel and potent catalytic approach that directly clears amyloid on the inside of neurons as well as reduces amyloid plaques...